|Articles|September 1, 1997

The Treatment of Hypercholesterolemia: A Managed Care Perspective
Volume 3
Issue 8 Suppl

Managing Comorbidities through Cholesterol-Lowering

Author(s)Alan O. Marcus, MD

Download PDF: Managing Comorbidities through Cholesterol-Lowering

Articles in this issue

about 29 years ago

Article

Goals and Objectives

about 29 years ago

Article

Introduction

about 29 years ago

Article

The Rationale for Treating Hypercholesterolemia

about 29 years ago

Article

Lowering Risk Factors through Cholesterol Treatment: Overview of the Recent Major Trials

about 29 years ago

Article

Preventing Coronary Heart Disease in the Managed Care Era: Improving the Cost Effectiveness of Lipid-Lowering Therapy with HMG-CoA Reductase Inhibitors

about 29 years ago

Article

Treating Hyperlipidemia to Prevent Coronary Heart Disease: What Are the Treatment Goals and How Do We Get There?

about 29 years ago

Article

CME Quiz

about 29 years ago

Article

Selected Abstracts

about 29 years ago

Article

Bibliography

about 29 years ago

Article

Participants

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Managing Comorbidities through Cholesterol-Lowering

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 August FDA Approvals Marked by Novelty, Pushback

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation